Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.
Category: Pharmacology
Study identifies therapeutic target for diabetic retinopathy
Specific cells in the retina trigger inflammation and vision impairment associated with diabetes, according to new research out of Case Western Reserve University School of Medicine. The findings unexpectedly implicate Mu Sller cells – which provide structural support in the retina – as key drivers of the process.
SLU researchers study a new way to lower LDL cholesterol
… not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms of use .
Correcting and Replacing Biocad: The first ever biosimilar of interferon beta-1a approved in Russia
The Ministry of Health of the Russian Federation has awarded Biocad marketing authorization for its interferon beta-1a biosimilar, a knockoff of Merck’s RebifA that is a key component in treatment of relapsing-remitting multiple sclerosis and included in all international recommendations and protocols. BIOCAD started the development program for interferon beta-1a biosimilar in 2012 and it took almost 5 years to run all the development phases, including pre-clinical/clinical studies and registration.
Biosimilar of costly inflammatory bowel disease therapy found safe and effective
Treatment of Crohn’s disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab , but at considerable cost. A recent analysis of results from 11 published studies including 829 patients shows that a new and lower-cost biosimilar for infliximab-called CT-P13 -has excellent clinical efficacy and safety.
BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos’ good…
BIOPHYTIS , a biotechnology company specializing in the development of drug candidates to treat diseases of ageing, announces today the complete results of the SARA-PK study, in particular the favorable pharmacokinetics and pharmacodynamics of Sarconeos. The analyses confirm the good pharmacokinetic profile in healthy elderly volunteers, the therapeutic window of Sarconeos, and confirms the dosages that will be tested in the Phase 2b trial SARA-INT.
Almost 2,000 opioid-related deaths in Massachusetts show fentanyl dangers rising
The increasing number of opioid-related deaths in Massachusetts show the state is one of the hardest hit in the nation by the growth of the highly-potent opioid fentanyl. The number of deaths related to opioids in Massachusetts has risen exponentially in recent years reaching an estimated 1,979 deaths this year, a sharp rise from 918 deaths in 2013, according to the Massachusetts Department of Public Health .
Smokers less likely to survive colon cancer Feb. 19, 2017, 10:23 PM Ast
… surgery, for example. And people who received chemo in addition to surgery might have been in generally better health than the surgery-only group. The study wasn’t a controlled experiment designed to prove that smoking causes colorectal cancer or …
Nicotine may help hold off Parkinsona s, Alzheimera s
… smoke,” Winzer-Serhan said. “Even if these weren’t very preliminary results, smoking results in so many health problems that any possible benefit of the nicotine would be more than canceled out.” Thousands of readers like you …
Curcumin helps to effectively ease inflammatory bowel disease: China mouse study
Curcumin can help suppress the activation of dendritic cells , which play a pivotal role in the progression of inflammatory bowel disease, research from China has discovered. Academics at Jiangxi University assessed if curcumin could represent a viable treatment alternative or adjunctive therapy in the management of chronic inflammatory bowel disease.
Cell Design Labs’ Scientific Founder Co-Authors Review Article…
Cell Design Labs, Inc. today announced that its scientific founder, Wendell Lim, Ph.D., co-authored a comprehensive review article on engineered cell therapies entitled, “The Principles of Engineering Immune Cells to Treat Cancer” in the current issue of the peer-reviewed journal Cell.
Newfound Effect of Cancer Drug May Expand its Use
… by a grants from the American Association for Cancer Research (AACR PanCAN 13-90-25-VOND), the National Institutes of Health (5-T32 CA 009161-39, 5-T32AI100853-04, and HL007151-36), and a Schwartz Fellowship.
Opiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil…
… of bringing new treatments to the people who need them.” Dr. Skolnick joins Opiant from the National Institute of Health, where he served as Director of the Division of Therapeutics and Medical Consequences, National Institute of Drug Abuse, since …
Addex’s Clinical Programs and Discovery Platform Highlighted in…
Addex Therapeutics announced today the publication of a review summarizing the current status of allosteric modulators as potential novel treatments for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease, in Current Opinion in Pharmacology . This review highlights the important contribution Addex has made in the discovery of allosteric modulator compounds.
‘Vulnerable’ man died after overdosing on mixture of drugs
Grant Burns was found in his room by support workers at the Booth Centre in Southampton on July 23 last year. The 35-year-old had a history of drug and alcohol abuse, and had been at the hostel for two years, Winchester Coroner’s Court heard.
Drugs firms profiteer from NHS by hiking cancer drugs prices
Drug companies are profiteering from the NHS to the tune of 1 billion because they have unjustifiably hiked prices of cancer medicine, experts warn. Cancer patients are let down by greedy drug companies who delay availability of well-established treatments and raise the prices beyond what the NHS can afford, academics said.
Some generic drugs prescribed for breast cancer are over-priced, specialist says.
… A 380 million a year across therapeutic areas through overcharging. Paying these high prices puts undue strain on health systems, and the long-term result “could be negative consequences for disease progression and survival”, the European Cancer …
LSD Effects On The Brain: Why Psychedelic Drug Makes Acid Trips Last…
… potent and long-lasting effects may help drug developers design psychiatric drugs that can target a variety of mental health conditions, with fewer side effects. LSD is also a semisynthetic member of a larger class of chemical compounds that are …
New DNA-Like Drugs Show Promise in Treating Alzheimer’s
Neurofibrillary tangles in the Hippocampus of an old person with Alzheimer-related pathology. Credit: Patho Wikimedia A growing body of research has traced the roots of Alzheimer’s disease to the deposition of a protein called tau throughout the brain.
This physician wants her patients to use fewer medications
… That means considering whether and what to prescribe while taking into consideration the patient’s age, other health conditions and overall life expectancy. As doctors, we need to ask ourselves, for example: For an 87-year-old woman with metastatic …
Researchers uncover mechanism of resistance used by triple negative breast cancer
Breast cancer cells are evasive, finding ways to bypass drugs designed to stop their unchecked growth. In a new study, researchers uncovered a mechanism of resistance used by a particularly aggressive breast cancer type, and revealed a possible drug combination that could stop cancer growth and also help to prevent resistance.
Insecticides mimic melatonin, creating higher risk for diabetes
… with standard wet-laboratory experiments. It was funded by a grant from the National Institute of Environmental Health Sciences, part of the National Institutes of Health. Disruptions in human circadian rhythms are known to put people at higher risk …
Insecticides mimic melatonin, creating higher risk for diabetes
… with standard wet-laboratory experiments. It was funded by a grant from the National Institute of Environmental Health Sciences, part of the National Institutes of Health. Disruptions in human circadian rhythms are known to put people at higher risk …
Two research studies on new molecules could potentially treat Alzheimer’s disease
This year, results have been published of two significant research studies about molecules that could potentially treat Alzheimer’s disease. The chief researcher in both studies was the head of the Laboratory of Medical Chemistry and Bioinformatics at MIPT Yan Ivanenkov.
The Silenced Child
Welcome to Childhood Made Crazy, an interview series that takes a critical look at the current “mental disorders of childhood” model. This series is comprised of interviews with practitioners, parents , and other children’s advocates as well as pieces that investigate fundamental questions in the mental health field.
Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424
Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it has entered into a collaboration with the National Cancer Institute , part of the National Institutes of Health , to study TH-3424, the company’s new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression.